A burst of disclosures
Advanced Medical Solutions (LSE:AMS), the Winsford-based maker of surgical tissue adhesives, sutures and wound dressings, published a cluster of regulatory filings on Monday 16 November 2026. They comprised a Takeover Code Rule 2.9 statement of its share capital, three major holdings notifications from Société Générale and a series of dealing disclosures by other investors. None changes the terms of the agreed cash Acquisition by a Subsidiary of US adhesives group H.B. Fuller, but together they show how the register is behaving while the deal waits for its remaining conditions.
What the filings say
The Rule 2.9 statement confirmed 221,193,292 ordinary shares of 5p in issue, with none in treasury. That compares with 221,189,604 three days earlier, on 13 November, and with 220,798,125 at the voting record time for the August Shareholder meetings. About 395,000 shares have been added since August, consistent with share plan awards being satisfied, although the filings do not state the cause.
The Société Générale notifications, all released on 16 November but covering earlier dates, show its voting interest falling to 3.93% on 9 November from 5.11%, rising to 5.12% on 11 November and dropping again to 4.61% on 12 November. Each reported holding was in ordinary shares rather than Derivatives or other instruments. The filings give no reason for the movements. Frequent crossings of the 5% threshold by a bank are more typical of trading or hedging activity than of a strategic stake, but that is interpretation.
Where the deal stands
The two sides agreed terms on 25 June 2026, and the scheme document followed on 20 July. At the court meeting on 12 August, 84.23% by value of scheme shares voted approved the scheme, with 15.77% against; votes cast represented 50.39% of the eligible share capital. The general meeting passed the special resolutions by the same proportion. In its interim results on 16 September, the company (LSE:AMS) said completion was expected in the fourth quarter of 2026, subject to outstanding conditions, and reported clearances or no-further-questions responses from authorities in Austria, Germany, the UK and under a waiting-period condition. On 22 October, H.B. Fuller said $850m of 7.625% notes due 2034, with existing cash, had replaced its bridge facility.
The Business meanwhile
In the six months to 30 June 2026, Revenue rose 4% to £115.5m and adjusted EBITDA increased 8% to £26.3m, while reported pre-tax profit fell to £0.3m after £12.4m of non-recurring costs linked to site consolidation and the takeover. Net Debt rose to £60.3m, and no Interim Dividend was declared. Surgical revenue grew 4% to £91.4m, held back by a 15% fall in US LiquiBand sales against a period flattered by partner order phasing, while Advanced (LSE:AMS) Woundcare grew 5% to £24.1m. Gross Margin improved to 54.5% from 53.5%. Manufacturing at five suture and collagen sites in Germany and Czechia is due to cease by the end of March 2027.
Factors to watch
Not every condition had been confirmed as satisfied in the documents reviewed, and the court sanction hearing has yet to be scheduled publicly. The long stop date is 25 June 2027, so delays would not by themselves end the deal, but they would postpone payment. The August vote also showed that a minority, holding 15.77% of the shares voted, opposed the deal, well short of a blocking position. Holdings notifications are snapshots and can be outdated by the time they are published.
What to watch
Shareholders should look for announcements on the remaining conditions and the sanction hearing date. Under the scheme timetable, dealings would be suspended two business days after the hearing, admission to AIM would be cancelled the business day after the effective date, and cash would be paid within 14 days.






Please wait processing your request...